<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

/x/   QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
      SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended December 31, 2000
                                       OR

/ /   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to _________________


                          Commission File Number 0-6516

                                DATASCOPE CORP.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                                          13-2529596
--------------------------------------------------------------------------------
(State of other jurisdiction of                         (I.R.S. Employer
 incorporation or organization)                        Identification No.)

               14 Philips Parkway, Montvale, New Jersey 07645-9998
--------------------------------------------------------------------------------
                    (Address of principal executive offices)

                                 (201) 391-8100
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)


Former name, former address and former fiscal year, if changed since last
report:

     Indicate by check mark whether the registrant
     (1) has filed all reports required to be filed by Section 13 or 15 (d) of
         the Securities Exchange Act of 1934 during the preceding 12 months (or
         for such shorter period that the registrant was required to file such
         reports), and
     (2) has been subject to such filing requirements for the past 90 days.

             YES  X       NO
                 ---         ---

Number of Shares of Company's Common Stock outstanding as of
January 31, 2001:  14,787,626.


<PAGE>
                        Datascope Corp. and Subsidiaries
                     Management's Discussion and Analysis of
                  Results of Operations and Financial Condition

Results of Operations

         Second quarter and first six months of fiscal 2001 compared to the
         corresponding periods last year.

     Net Sales
     ---------

         Net sales were $75.5 million in the second quarter and $143.3 million
         in the first six months of fiscal 2001 representing an increase of 1%
         and 4% compared to the second quarter and first six months of fiscal
         2000.

         Sales of the Cardiac Assist / Monitoring Products segment were $55.3
         million compared to $56.3 million in the second quarter and $105.1
         million in the first six months of fiscal 2001 compared to $103.2
         million last year.

         Sales in the second quarter were below plan, primarily because the
         company's supplier of printed circuit boards could not produce the
         quantities needed to support planned requirements for Passport 2
         patient monitors and System 98 balloon pumps. The company anticipates
         that the board deliveries in the third quarter will be adequate to
         support planned shipments. In addition, Datascope has contracted with a
         second supplier who will begin shipping boards in the fourth quarter.

              Sales of intra-aortic balloon catheters increased due to higher
              international shipments and significantly increased market
              penetration of the Profile 8 Fr. product, accounting for 60% of
              worldwide balloon catheter sales in the second quarter this year
              compared to 50% in the same period last year. Customer demand has
              been strong for the System 98XT balloon pump, a new advanced
              performance balloon pump, launched in the second quarter that
              replaces the System 98.

              Primarily as a result of the supplier-related shortfall for
              circuit boards, Patient Monitoring sales in the second quarter
              declined 4% to $25.9 million.

         Sales of the Collagen Products / Vascular Grafts segment increased 10%
         to $20.2 million in the second quarter and 9% to $38.2 million in the
         first six months of fiscal 2001.

              Sales of VasoSeal(R) arterial puncture sealing devices increased
              6% to $14.1 million. In order to compete more effectively in the
              vascular sealing market, Datascope is completing the previously
              announced 20% expansion of its field sales organization, and
              expects that training will be completed in the third quarter. The
              company expects that this expansion will begin to contribute to
              sales in the fourth quarter.


<PAGE>
              InterVascular sales increased 15% to $5.7 million, due to
              continued strong international demand for the InterGard
              Silver(TM), the world's first anti-microbial vascular graft. In
              addition, sales to the U.S. distributor increased significantly
              for the second consecutive quarter, reversing the sharp decline in
              sales of last year as the distributor reduced inventory. Excluding
              foreign exchange adjustment, InterVascular's sales rose 26% in the
              second quarter.

              InterVascular received FDA 510(k) clearance in January to market
              the company's line of heparin-coated vascular grafts, InterGard
              Heparin(TM), in the U.S. InterGard Heparin is the first vascular
              prosthesis incorporating a drug cleared for marketing by the FDA.
              Shipments are expected to begin in the fourth quarter. InterGard
              Heparin has been successfully implanted in more than 15,000
              patients since its introduction in Europe in 1993.

         The stronger U.S. dollar compared to major European currencies
         decreased total sales by approximately $1.7 million in the second
         quarter and $2.8 million in the first six months of fiscal 2001.

     Gross Profit (Net Sales Less Cost of Sales)
     -------------------------------------------

         The gross profit percentage was 61.1 % for the second quarter and 60.6%
         for the first six months of fiscal 2001, compared to 61.3% and 61.6%
         for the corresponding periods last year. The gross profit percentage in
         the second quarter and first six months of fiscal 2001 was impacted
         primarily by lower average selling prices for certain patient
         monitoring products and one-time incremental costs related to the
         shortfall in circuit board supply.

     Research and Development (R&D)
     ------------------------------

         R&D expenses, as a percentage of sales, were 8.0% for the second
         quarter and 8.6% for the first six months of fiscal 2001, compared to
         8.1 % and 9.1 % for the corresponding periods last year.

         R&D expenses were $6.0 million in the second quarter and $12.3 million
         in the first six months of fiscal 2001 compared to $6.1 million and
         $12.6 million for the corresponding periods last year. The decrease was
         primarily due to reduced development expenses in the Patient Monitoring
         product line.

     Selling, General & Administrative Expenses (SG&A)
     -------------------------------------------------

         SG&A expenses, as a percentage of sales, were 38.3% in the second
         quarter and 39.0% in the first six months of fiscal 2001, compared to
         40.1% and 40.9% in the corresponding periods last year.

         SG&A expenses declined $1.1 million or 4% in the second quarter and
         $0.7 million or 1% in the first six months of fiscal 2001 primarily as
         a result of tighter operating cost controls and reduced corporate
         expenses.

<PAGE>
         The stronger U.S. dollar compared to major European currencies
         decreased SG&A expenses by approximately $1.2 million in the second
         quarter and $1.9 million in the first six months of fiscal 2001.

     Interest Income and Expense
     ---------------------------

         Interest income in the second quarter of $0.9 million, was unchanged
         compared to the second quarter last year. Interest income was $2.0
         million for the first six months of fiscal 2001 compared to $1.7
         million last year, with the 15% increase attributable to an increase in
         the average yield to 6.1% from 5.4%. The portfolio balance declined
         from $62.5 million to $58.1 million.

         In the first quarter of fiscal 2001 we recorded a pretax gain of $593
         thousand, or $0.02 per share after tax, from the sale of an
         underutilized facility in Oakland, New Jersey.

     Income Taxes
     ------------

         The consolidated effective tax rate was 32.0% for the second quarter
         and first six months of fiscal 2001 compared to 31.0% for the
         corresponding periods last year. The higher tax rate in fiscal 2001 was
         due mainly to the impact of higher earnings taxed at a higher statutory
         tax rate and expiration of a tax exemption for a manufacturing
         subsidiary in Europe.

     Net Earnings
     ------------

         Net earnings increased 11% to $8.2 million or $0.53 per diluted share
         in the second quarter of fiscal 2001 compared to $7.4 million, or $0.46
         per diluted share last year. Net earnings for the first six months of
         fiscal 2001 increased 17% to $14.3 million or $0.92 per diluted share
         compared to $12.2 million or $0.76 per diluted share for the first six
         months last year.

         The increased earnings reflect:
             o    higher gross margin from increased sales
             o    greater expense control
             o    non-recurring gain of $593 thousand or $0.02 per diluted share
                  after tax related to the sale of an underutilized facility,
                  recorded in the first quarter

Liquidity and Capital Resources

     Working capital was $125.5 million at December 31, 2000, compared to $120.8
     million at June 30, 2000. The current ratio was 3.6:1 compared to 3.3:1.

     In the first six months of fiscal 2001 cash provided by operations was $4.3
     million, compared to $12.4 million last year. The decline is primarily
     attributable to a reduction in accrued liabilities and an increase in
     accounts receivable. Net cash provided by investing activities was $3.1
     million, primarily attributable to maturities of marketable securities of
     $36.8 million, partially offset by $28.9 million purchases of marketable
     securities and the purchase of $5.9 million of property, plant and
     equipment. Net cash used in financing activities was $6.8 million,
     primarily due to stock repurchases of $6.5 million and $0.6 million
     dividends paid.


<PAGE>

     Through December 31, 2000 we expended $6.5 million to purchase about
     190,000 shares of our common stock under the current $30 million stock
     repurchase program.

     On December 12, 2000 the Board of Directors declared an increase in the
     quarterly dividend to $0.05 per share payable on January 12, 2001 to
     stockholders of record at December 27, 2000.

     We believe our financial resources are sufficient to meet our projected
     cash requirements.

     The moderate rate of current U.S. inflation has not significantly affected
     the company.

Euro Conversion

     As part of the European Economic and Monetary Union (EMU), a single
     currency (Euro) will replace the national currencies of most of the
     European countries in which we conduct our business. The conversion rates
     between the Euro and the participating nations' currencies have been fixed
     irrevocably as of January 1, 1999. During a transition period from January
     1, 1999 to December 31, 2001 parties may settle transactions using either
     Euro or the participating country's national currency. The participating
     national currencies will be removed from circulation between January 1,
     2002 and June 30, 2002 and replaced by Euro notes and coinage. Full
     conversion of all affected country operations to the Euro currency is
     expected to be completed by the time national currencies are removed from
     circulation.

     We are currently involved in the phased conversion to the Euro and the
     effects on revenues, costs and various business strategies are being
     assessed. We are able to conduct business in both the Euro and national
     currencies on an as needed basis, as required by the European Union. The
     cost of software and business process conversion is not expected to be
     material to our financial condition or results of operations.

Information Concerning Forward Looking Statements

     This Management's Discussion and Analysis of Results of Operations and
     Financial Condition includes forward-looking statements that involve risks
     and uncertainties because of the possibility that market conditions may
     change, particularly as the result of competitive activity in the cardiac
     assist, arterial sealing and other markets served by the company, the
     company's ability to gain market acceptance for new products and the
     company's dependence on certain suppliers for patient monitoring, cardiac
     assist and VasoSeal products. Additional risks are the ability of the
     company to successfully introduce new products, continued demand for the
     company's products generally, the rapid and significant changes that
     characterize the medical device industry and the ability to continue to
     respond to such changes, the uncertain timing of regulatory approvals, as
     well as other risks detailed from time to time in documents filed by
     Datascope with the Securities and Exchange Commission.


<PAGE>

Quantitative and Qualitative Disclosures About Market Risk

     Due to the global nature of our operations, we are subject to the exposures
     that arise from foreign exchange rate fluctuations. Our objective in
     managing the exposure to foreign currency fluctuations is to minimize net
     earnings volatility associated with foreign exchange rate changes. We enter
     into foreign currency forward exchange contracts to hedge a substantial
     portion of the foreign currency transactions which are primarily related to
     certain intercompany receivables denominated in foreign currencies. Our
     hedging activities do not subject us to exchange rate risk because gains
     and losses on these contracts offset losses and gains on the assets,
     liabilities and transactions being hedged.

     We do not use derivative financial instruments for trading purposes. None
     of our foreign currency forward exchange contracts are designated as
     economic hedges of our net investment in foreign subsidiaries.

     As of December 31, 2000, we had a notional amount of $4.8 million of
     foreign exchange forward contracts outstanding, all of which were in
     European currencies. The foreign exchange forward contracts generally have
     maturities that do not exceed 12 months and require us to exchange foreign
     currencies for U.S. dollars at maturity, at rates agreed to when the
     contract is signed.




<PAGE>

                        Datascope Corp. and Subsidiaries
                           Consolidated Balance Sheets
                                 (In thousands)
<TABLE>
<CAPTION>

                                                                           Dec 31,             June 30,
                                                                            2000                 2000
                                                                          ---------           ---------
Assets                                                                   (unaudited)              (a)
<S>                                                                       <C>                  <C>
Current Assets:
  Cash and cash equivalents                                               $   2,469            $   2,102
  Short-term investments                                                     47,283               53,096
  Accounts receivable less allowance for
    doubtful accounts of $1,670 and $1,644                                   67,767               69,081
  Inventories                                                                44,647               38,986
  Prepaid expenses and other current assets                                  11,964               10,014
                                                                          ---------            ---------
      Total Current Assets                                                  174,130              173,279

Property, Plant and Equipment, net of accumulated
    depreciation of $61,469 and $58,234                                      89,486               86,243
Non-Current Marketable Securities                                            10,098               12,235
Other Assets                                                                 23,880               23,034
                                                                          ---------            ---------
                                                                          $ 297,594            $ 294,791
                                                                          =========            =========

Liabilities and Stockholders' Equity
Current Liabilities:
  Accounts payable                                                        $  14,879            $  14,250
  Accrued expenses                                                           16,005               11,165
  Accrued compensation                                                       12,383               19,662
  Deferred revenue                                                            3,797                4,773
  Taxes on income                                                             1,547                2,630
                                                                          ---------            ---------
      Total Current Liabilities                                              48,611               52,480

Other Liabilities                                                            14,812               14,524
Stockholders' Equity
  Preferred stock, par value $1.00 per share:
    Authorized 5 million shares; Issued, none                                    --                   --
  Common stock, par value $.01 per share:
    Authorized, 45 million shares; Issued and
    outstanding, 17,132 and 17,028 shares                                       171                  170
  Additional paid-in capital                                                 60,963               60,646
  Treasury stock at cost, 2,339 and 2,149 shares                            (61,731)             (55,247)
  Retained earnings                                                         243,101              230,187
  Accumulated other comprehensive loss                                       (8,333)              (7,969)
                                                                          ---------            ---------
                                                                            234,171              227,787
                                                                          ---------            ---------
                                                                          $ 297,594            $ 294,791
                                                                          =========            =========
</TABLE>
                  (a) Derived from audited financial statements
                 See notes to consolidated financial statements

<PAGE>
                        Datascope Corp. and Subsidiaries
                       Statements of Consolidated Earnings
                    (In thousands, except per share amounts)
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                Six Months Ended                   Three Months Ended
                                                                  December 31,                         December 31,
                                                         ----------------------------          ---------------------------
                                                            2000               1999               2000              1999
                                                         ---------          ---------           --------          --------
<S>                                                      <C>                <C>                 <C>               <C>
Net Sales                                                $ 143,300          $ 138,300           $ 75,500          $ 74,800
                                                         ---------          ---------           --------          --------
Costs and Expenses:
  Cost of sales                                             56,462             53,125             29,390            28,911
  Research and development
    expenses                                                12,304             12,562              6,048             6,065
  Selling, general and
    administrative expenses                                 55,938             56,593             28,908            29,987
                                                         ---------          ---------           --------          --------
                                                           124,704            122,280             64,346            64,963
                                                         ---------          ---------           --------          --------
Operating Earnings                                          18,596             16,020             11,154             9,837

Other (Income) Expense:
  Interest income                                           (1,988)            (1,722)              (890)             (855)
  Interest expense                                               9                 10                  7                 8
  Other, net                                                  (381)                50                 27                 2
                                                         ---------          ---------           --------          --------
                                                            (2,360)            (1,662)              (856)             (845)
                                                         ---------          ---------           --------          --------
Earnings Before Taxes on Income                             20,956             17,682             12,010            10,682

Taxes on Income                                              6,706              5,481              3,843             3,311
                                                         ---------          ---------           --------          --------
Net Earnings                                             $  14,250          $  12,201           $  8,167          $  7,371
                                                         =========          =========           ========          ========

Earnings Per Share, Basic                                $    0.96          $    0.81           $   0.55          $   0.49
                                                         =========          =========           ========          ========
Weighted average common
   shares outstanding, Basic                                14,827             15,101             14,796            14,995
                                                         =========          =========           ========          ========

Earnings Per Share, Diluted                              $    0.92          $    0.76           $   0.53          $   0.46
                                                         =========          =========           ========          ========
Weighted average common
   shares outstanding, Diluted                              15,490             16,053             15,385            16,002
                                                         =========          =========           ========          ========

</TABLE>
                 See notes to consolidated financial statements


<PAGE>
                        Datascope Corp. and Subsidiaries

                      Statements of Consolidated Cash Flows
                             (Dollars in thousands)

                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                           Six Months Ended
                                                                              December 31
                                                                        ------------------------
                                                                          2000            1999
                                                                        -------         --------
<S>                                                                     <C>             <C>
Operating Activities:
  Net cash provided by operating activities                             $ 4,261         $ 12,402
                                                                        -------         --------

Investing Activities:
  Capital expenditures                                                   (5,923)          (8,173)
  Proceeds from sale of Oakland facility                                  1,112                0
  Purchases of marketable securities                                    (28,892)         (40,253)
  Maturities of marketable securities                                    36,842           42,536
                                                                        -------         --------
  Net cash provided by (used in) investing activities                     3,139           (5,890)
                                                                        -------         --------

Financing Activities:
  Treasury shares acquired under repurchase programs                     (6,484)         (10,347)
  Exercise of stock options and other                                       318            2,205
  Cash dividends paid                                                      (595)               0
                                                                        -------         --------
  Net cash used in financing activities                                  (6,761)          (8,142)
                                                                        -------         --------

  Effect of exchange rates on cash                                         (272)             125
                                                                        -------         --------

Increase (decrease) in cash and cash equivalents                            367           (1,505)
Cash and cash equivalents, beginning of period                            2,102            4,572
                                                                        -------         --------

Cash and cash equivalents, end of period                                $ 2,469         $  3,067
                                                                        =======         ========

Supplemental Cash Flow Information
  Cash Paid during the period for:
   Income taxes                                                         $ 7,792         $  5,426
                                                                        -------         --------
  Non-cash transactions:
   Net transfers of inventory to fixed assets
    for use as demonstration equipment                                  $ 4,047         $  4,312
                                                                        -------         --------
</TABLE>

                 See notes to consolidated financial statements


<PAGE>
                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

1.  Basis of Presentation

The consolidated financial statements include the accounts of Datascope Corp.
and its subsidiaries (the "Company" - which may be referred to as "our", "us" or
"we").

The consolidated balance sheet as of December 31, 2000, the statements of
consolidated earnings for the three and six month periods ended December 31,
2000 and 1999 and the statements of cash flows for the six month periods ended
December 31, 2000 and 1999 have been prepared by the Company, without audit. In
our opinion, all adjustments (which include only normal recurring adjustments)
have been made that are necessary to present fairly the financial position,
results of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. We suggest that you read these condensed
consolidated financial statements in conjunction with the financial statements
and notes included in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2000. The results of operations for the period ended December 31, 2000
are not necessarily indicative of a full year's operations.

We have reclassified certain prior year information to conform with the current
year presentation.

2.  Inventories

Inventories are stated at the lower of cost or market, with cost determined on a
first-in, first-out basis.

                                            Dec 31,        June 30,
                                             2000            2000
                                           -------         -------
                 Materials                 $23,292         $17,462
                 Work in Process             9,321           7,888
                 Finished Goods             12,034          13,636
                                           -------         -------
                                           $44,647         $38,986
                                           =======         =======

3.  Stockholders' Equity

Changes in the components of stockholders' equity for the six months ended
December 31, 2000 were as follows:

                 Net earnings                                     $14,250
                 Foreign currency translation adjustments            (364)
                 Common stock and additional paid-in
                   capital effects of stock option activity           318
                 Cash dividends on common stock                    (1,336)
                 Purchases under stock repurchase plans            (6,484)
                                                                  -------
                 Total increase in stockholders' equity           $ 6,384
                                                                  =======

<PAGE>
                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

4.  Earnings Per Share

In accordance with Financial Accounting Standard No. 128, "Earnings Per Share",
we disclose both Basic and Diluted Earnings Per Share. The reconciliation of
Basic Earnings Per Share to Diluted Earnings Per Share is as follows:
<TABLE>
<CAPTION>
---------------------------------      --------------------------------------------------------------------------------------
For Three Months Ended                            December 31, 2000                          December 31, 1999
---------------------------------      --------------------------------------------------------------------------------------
                                           Net                     Per Share             Net                      Per Share
Basic EPS                               Earnings        Shares       Amount            Earnings       Shares        Amount
---------                              ------------  ------------  ------------       ------------  ------------  -----------
<S>                                         <C>           <C>           <C>                <C>           <C>           <C>
Earnings available to
   common shareholders                      $8,167        14,796         $0.55             $7,371        14,995        $0.49

Diluted EPS

Options issued to employees                     --           589         (0.02)                --         1,007        (0.03)
                                       ------------  ------------  ------------       ------------  ------------  -----------

Earnings available to
   common shareholders
   plus assumed conversions                 $8,167        15,385         $0.53             $7,371        16,002        $0.46
                                       ============  ============  ============       ============  ============  ===========
</TABLE>
<TABLE>
<CAPTION>
---------------------------------      --------------------------------------------------------------------------------------
For Six Months Ended                              December 31, 2000                          December 31, 1999
---------------------------------      --------------------------------------------------------------------------------------
                                           Net                      Per Share             Net                      Per Share
Basic EPS                               Earnings       Shares         Amount            Earnings       Shares        Amount
---------                              ------------  ------------  ------------       ------------  ------------  -----------
<S>                                        <C>            <C>            <C>              <C>            <C>           <C>
Earnings available to
   common shareholders                     $14,250        14,827         $0.96            $12,201        15,101        $0.81

Diluted EPS

Options issued to employees                     --           663         (0.04)                --           952        (0.05)
                                       ------------  ------------  ------------       ------------  ------------  -----------

Earnings available to
   common shareholders
   plus assumed conversions                $14,250        15,490         $0.92            $12,201        16,053        $0.76
                                       ============  ============  ============       ============  ============  ===========
</TABLE>

5.  Comprehensive Income

In accordance with Financial Accounting Standard No. 130, "Reporting
Comprehensive Income", we disclose comprehensive income and its components. For
the three and six month periods ended December 31, 2000 and 1999 our
comprehensive income was as follows:
<TABLE>
<CAPTION>
                                             Six Months Ended                Three Months Ended
                                         --------------------------       --------------------------
                                          12/31/00      12/31/99           12/31/00      12/31/99
                                         ------------  ------------       ------------  ------------
       <S>                                   <C>           <C>                 <C>           <C>
       Net earnings                          $14,250       $12,201             $8,167        $7,371
       Foreign currency translation
          gain or (loss)                        (364)         (416)             1,278        (1,108)
                                         ------------  ------------       ------------  ------------
       Total comprehensive income            $13,886       $11,785             $9,445        $6,263
                                         ============  ============       ============  ============
</TABLE>
<PAGE>
                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

6.  Segment Information

Our business is the development, manufacture and sale of medical devices. We
have two reportable segments, Cardiac Assist / Monitoring Products and Collagen
Products / Vascular Grafts.

The Cardiac Assist / Monitoring Products segment includes electronic
intra-aortic balloon pumps and catheters that are used in the treatment of
vascular disease and electronic physiological monitors that provide for patient
safety and management of patient care.

The Collagen Products / Vascular Grafts segment includes extravascular
hemostasis devices which are used to seal arterial puncture wounds to stop
bleeding after cardiovascular catheterization procedures and a proprietary line
of knitted and woven vascular grafts and patches for reconstructive vascular and
cardiovascular surgery.

We have aggregated our product lines into two segments based on similar
manufacturing processes, distribution channels, regulatory environments and
customers. Management evaluates the revenue and profitability performance of
each of our product lines to make operating and strategic decisions. We have no
intersegment revenue. Net sales and operating earnings are shown below.
<TABLE>
<CAPTION>
                                                           Cardiac          Collagen
                                                           Assist/          Products/        Corporate
                                                         Monitoring         Vascular            and
                                                          Products           Grafts            Other          Consolidated
-----------------------------------------------------   --------------    --------------   --------------    ----------------
Three months ended December 31, 2000
-----------------------------------------------------
<S>                                                           <C>               <C>                 <C>              <C>
Net sales to external customers                               $55,254           $20,246               --             $75,500
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                             $6,649            $3,754             $752             $11,154
                                                        --------------    --------------   --------------    ----------------

-----------------------------------------------------
Three months ended December 31, 1999
-----------------------------------------------------
Net sales to external customers                               $56,343           $18,457               --             $74,800
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                             $7,892            $2,500            ($555)             $9,837
                                                        --------------    --------------   --------------    ----------------

-----------------------------------------------------
Six months ended December 31, 2000
-----------------------------------------------------
Net sales to external customers                              $105,073           $38,227               --            $143,300
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                             $9,839            $7,184           $1,574             $18,596
                                                        --------------    --------------   --------------    ----------------

-----------------------------------------------------
Six months ended December 31, 1999
-----------------------------------------------------
Net sales to external customers                              $103,161           $35,139               --            $138,300
                                                        --------------    --------------   --------------    ----------------
Operating earnings                                            $11,142            $5,891          ($1,013)            $16,020
                                                        --------------    --------------   --------------    ----------------
</TABLE>
<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
Reconciliation to consolidated earnings                          Six Months Ended                   Three Months Ended
    before income taxes :                                   12/31/00         12/31/99         12/31/00          12/31/99
-----------------------------------------------------   --------------    --------------   --------------    ----------------
<S>                                                           <C>               <C>              <C>                  <C>
Consolidated operating earnings                               $18,596           $16,020          $11,154              $9,837
Interest income, net                                            1,979             1,712              883                 847
Other (expense) income                                            381               (50)             (27)                 (2)
                                                        --------------    --------------   --------------    ----------------
Consolidated earnings before taxes                            $20,956           $17,682          $12,010             $10,682
                                                        ==============    ==============   ==============    ================
</TABLE>

<PAGE>
                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

7.  Restructuring Program

Based upon a review by senior management of all company operations, a
restructuring plan was approved in fiscal year 1999 to reduce the company's cost
structure and streamline certain operations. We recorded pretax restructuring
charges totaling $3.43 million, or $0.14 per share, during the second half of
fiscal 1999 related to the following cost reduction initiatives:

     o   Closure of InterVascular's Clearwater, Florida leased manufacturing
         facility in order to reduce costs and centralize operations in our
         expanded manufacturing facility in LaCiotat, France.

     o   Workforce reductions in certain administrative, R&D and manufacturing
         positions throughout the company.

     o   Writedown of certain Genisphere fixed assets based on the revised
         market entry strategy for the proprietary 3DNA technology. Under the
         revised market entry stategy we will focus product development on
         improving the performance of newly-developing technologies for drug
         discovery used by the pharmaceutical and biotech industries.

As of December 31, 2000, the remaining liability for the restructuring is $228
thousand for employee severance and $56 thousand in lease termination costs. No
additional expenditures are expected to complete the restructuring program.


<PAGE>

Part II:

    Item 6.   Exhibits and Reports on Form 8-K

              a.  Exhibits

                  none

              b.  Reports on Form 8-K.  No reports on Form 8-K have been filed
                  during the quarter for which this report is filed.



<PAGE>
                                                                       Form 10-Q


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                  DATASCOPE CORP.
                                  Registrant


                                  By: \s\   Lawrence Saper
                                      -----------------------------------
                                        Chairman of the Board and
                                        Chief Executive Officer


                                  By: \s\   Leonard S. Goodman
                                      -----------------------------------
                                        Vice President, CFO and Treasurer


Dated: February 9, 2001